Hematologic Malignancies Talk: Exciting Updates from ASH 2020 Virtual Meeting - Episode 2

ASH 2020 Updates in Non-CLL B-Cell Lymphomas

January 22, 2021
Jennifer Woyach, MD, Ohio State University

Matthew S. Davids, MD, MMSc, Dana-Farber Cancer Institute

Nathan H. Fowler, MD, MD Anderson Cancer Center

Sarah Rutherford, MD, Weill Cornell Medical College

Key opinion leaders provide insight into data updates from the ASH (American Society of Hematology) 2020 Annual Meeting on developments in agents for the management of non-CLL (chronic lymphocytic leukemia) B-cell lymphomas.

Data from the following clinical trials are discussed:

  • Abstract 2109: Selinexor in Combination with R-CHOP for Front-Line Treatment of Non-Hodgkin Lymphoma: Results of a Phase 1b Study

  • Abstract 405: Interim Analysis of ZUMA-12: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as First-Line Therapy in Patients (Pts) With High-Risk Large B Cell Lymphoma (LBCL)